California Pharmacy Law Exam

🩺 Clinical Practice: Determining a Course of Action

What this topic covers

Part 2A of the 2022 content outline: deciding on a course of action, including pharmacist-furnished contraception, smoking cessation, naloxone, travel medications, HIV prophylaxis, COVID-19 antivirals, immunizations, collaborative practice and drug therapy problems found in FDA labeling. These are original practice notes, not materials of the California State Board of Pharmacy or PSI, based on the texts in force on January 1, 2027. Time limits, thresholds and quantities can change with each year's legislation. Nothing here is medical advice.

Contraception

Smoking cessation

Naloxone, travel, HIV and COVID-19

Collaborative and advanced practice

Labeled drug problems

Take the free test · full question bank and mock exams with a subscription

Sample questions (5)

1. A patient asks pharmacist Dana Ortiz at Cedar Hill Pharmacy for emergency contraception. She does not want to discuss her health history or name a physician. The pharmacist should

  1. refuse until she names her primary care provider
  2. refuse until she lists her past contraceptive use
  3. furnish it after collecting only 1707.1 information
  4. ask her to obtain a prescription from a prescriber

Business and Professions Code section 4052(a)(10)(A)(i) provides that a pharmacist “shall not require a patient to provide individually identifiable medical information” that is not specified in 16 CCR section 1707.1 before initiating emergency contraception, and 16 CCR section 1746(b)(4) tells the pharmacist to collect the 1707.1 patient medication record information. The pharmacist therefore furnishes the product after collecting only that information. Refusing until she lists past contraceptive use adds a condition the law does not allow, and no prescription is needed because the pharmacist furnishes under section 4052(a)(10). Her refusal to name a physician does not block furnishing: under section 4052(e), a patient who has no primary care provider or asks that none be notified receives a written or electronic record of the drug furnished.

2. Patient L.T., 24 years old, asks for emergency contraception about 96 hours (4 days) after unprotected intercourse. Which product is labeled for use at this time?

  1. levonorgestrel, labeled for use within 72 hours
  2. levonorgestrel, labeled for use within 120 hours
  3. ulipristal, labeled for use within 72 hours
  4. ulipristal, labeled for use within 120 hours

The ella prescribing information (section 2) directs one tablet “as soon as possible, within 120 hours (5 days) after unprotected intercourse”, so ulipristal is labeled for use at 96 hours. The Plan B One-Step Drug Facts label (Directions), dated January 2023 and still the latest published version, says to take levonorgestrel “as soon as possible within 72 hours (3 days)”, so it is not labeled for this time; 16 CCR section 1746 also notes that after 72 hours ulipristal may be more effective than levonorgestrel. The options pairing levonorgestrel with 120 hours or ulipristal with 72 hours swap the two labeled windows.

3. A patient taking Opill (norgestrel 0.075 mg) realizes she took today's tablet 5 hours late. Per the Opill Drug Facts label, the pharmacist should advise her to

  1. take 1 tablet now and use a condom for the next 2 days
  2. take 2 tablets now and use a condom for the next 2 days
  3. skip the late tablet and use a condom for the next 7 days
  4. take 1 tablet now and rely on it without a condom

The Opill Drug Facts label (Directions) states that when she is more than 3 hours late she should “take 1 tablet immediately, as soon as you remember that you missed it” and then return to her usual time. It also tells her to use a condom or another barrier method every time she has sex during the next 2 days (48 hours). Two tablets are not in the directions, a 7-day barrier period is not in the label, and omitting the barrier method ignores the 48-hour instruction.

4. Patient P.S., 31 years old, buys Opill and mentions that she also uses a contraceptive vaginal ring. What should the pharmacist tell her about this combination?

  1. The two products can be used together for extra protection
  2. Opill should not be taken together with the vaginal ring
  3. Opill can be added to the ring if she also uses a condom
  4. Opill can be added to the ring once 2 days have passed

The Opill Drug Facts label (Do not use) lists use “together with another birth control pill, vaginal ring, patch, implant, injection or an IUD” among the reasons not to use the product. Adding a condom or waiting 2 days does not remove that warning; the 48-hour barrier method applies to starting the first pack, a late tablet, or vomiting. The pharmacist therefore advises against combining the two.

5. Patient R.M. receives contraception furnished by pharmacist Luis Navarro at Harbor Lane Pharmacy. R.M. says she has no primary care provider. What must the pharmacist do to comply with Business and Professions Code section 4052(a)(10)?

  1. Give her a written record and advise her to consult a physician
  2. Notify the Board of Pharmacy of the furnishing within 24 hours
  3. Decline to furnish until she identifies a physician of her choice
  4. Keep a note in the pharmacy records and do nothing further

Section 4052(a)(10)(B) provides that if the patient “does not have a primary care provider, the pharmacist shall provide the patient with a written record” of the drugs or devices furnished and advise the patient to consult a physician. A pharmacy-only note does not meet that duty, and refusing to furnish adds a condition the statute does not contain. Notice to the Board of Pharmacy is not part of this provision.

Start free

California Pharmacy Law Exam · Topics · Exam guide · Sample questions